The role of small intestinal bacterial overgrowth in Parkinson's disease

Alfonso Fasano1, Francesco Bove, Maurizio Gabrielli

  • 1Department of Neurology, Catholic University of Sacred Heart, Gemelli University Hospital, Rome, Italy. alfonso.fasano@gmail.com

Insights

Small intestinal bacterial overgrowth is more common in Parkinson's disease patients and linked to motor fluctuations. Treating this overgrowth improves symptoms without impacting levodopa levels.

Area of Science:

  • Neurology
  • Gastroenterology
  • Microbiology

Background:

  • Parkinson's disease (PD) is linked to gastrointestinal issues, potentially increasing local infections.
  • Gastrointestinal motility abnormalities in PD may promote infections, influencing disease progression.

Purpose of the Study:

  • To investigate if small intestinal bacterial overgrowth (SIBO) contributes to motor fluctuations in Parkinson's disease.
  • To assess the impact of SIBO eradication on motor fluctuations and levodopa pharmacokinetics.

Main Methods:

  • Breath tests (glucose, lactulose, urea) and ultrasonography were used in 33 PD patients and 30 controls.
  • Clinical status, levodopa levels, and motor fluctuations (UPDRS-IV, diaries) were assessed before and after rifaximin treatment for SIBO.

Main Results:

  • SIBO prevalence was higher in PD patients (54.5%) than controls (20.0%).
  • Patients with SIBO experienced more unpredictable motor fluctuations and longer 'off' times.
  • Rifaximin treatment eradicated SIBO, improving motor fluctuations without altering levodopa pharmacokinetics; 43% relapse rate at 6 months.

Conclusions:

  • SIBO is a significant factor in motor fluctuations for Parkinson's disease patients.
  • Eradication of SIBO offers a potential therapeutic strategy for managing motor symptoms in PD.

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Irritable Bowel Syndrome01:23

Irritable Bowel Syndrome

DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...